1. Scrip
  2. >>New Products

Rinvoq Approved For Crohn’s Disease In Pivotal Year For AbbVie’s Immunology Business

7th US Indication For The JAK Inhibitor, 2nd In IBD

 
• By Mandy Jackson

US FDA approval in Crohn’s disease further boosts the revenue potential for Rinvoq as AbbVie navigates a period of declining sales overall due to the introduction of US biosimilars for Humira. 

Intestines health. Guts on pink background top view copy space
Rinvoq is now approved in the US for two inflammatory bowel disease indications • Source: Shutterstock

The US Food and Drug Administration approval of AbbVie Inc.’s Rinvoq (upadacitinib) for Crohn’s disease is the drug’s second inflammatory bowel disease (IBD) indication and seventh indication overall, increasing the JAK inhibitor’s revenue potential at a crucial time for the company. Sales for Humira (adalimumab) are in decline with the introduction of the first US biosimilars of the top-seller in AbbVie’s powerhouse immunology franchise, resulting in lower overall revenue for the company in 2023.

AbbVie hopes that combined sales of Rinvoq and the interleukin-23 inhibitor Skyrizi (risankizumab) will eventually fill the Humira revenue deficit. The company has guided for $11.1bn in sales from the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

 
• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.

Pipeline Watch: Eight Approvals And Nineteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

More from Scrip

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.